nysegsk
Shares of Sanofi were up 10.20% the week ended March 24, while Regeneron finished with a gain of 9.68%, following promising news about the company’s jointly developed medication Dupixent.Clinical trial results showed the drug reduced severe flare-ups of COPD at a far better rate than a placebo.There are currently no equivalent treatments for COPD, meaning the drug has blockbuster potential, once approved.Analysts expect Dupixent sales to total $20 billion by the end of the decade.Wall Street has boosted price targets for both companies.5 stocks we like better than SanofiQ4 2022 hedge fund lett...
ValueWalk
GlaxoSmithKline (LON:GSK) reported second quarter sales of £8.1bn, up 15% at constant exchange rates (CER). That reflects particularly strong growth in Pharmaceuticals and Vaccines businesses. Q2 2021 hedge fund letters, conferences and more Underlying operating profits rose 43% to £2.2bn as the group benefited from a weaker comparator, due to de-stocking in both pharmaceuticals and consumer healthcare in the same period last year, and ongoing cost savings. The group announced a dividend of 19p per share for the quarter and continues to expect full year dividends to hit 80p. GSK shares rose 2....
ValueWalk
GlaxoSmithKline plc (NYSE:GSK) (LON:GSK) shares reacted positively at first to the release of Q1 results at midday today, although doubts subsequently set in, with the shares surrendering much of their early gains.Q1 2021 hedge fund letters, conferences and more The company reported a sharp reduction in income due to a tough comparison a year previously, plus the impact of reduced patient visits to their GPs and a muted colds and flu season this year. Underlying sales dropped by 15%, and adjusted earnings were some 33% lower than the previous year.A Weak Quarter For GlaxoSmithKlineCommenting o...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら